Syngeneic Syrian hamster tumors feature tumor-infiltrating lymphocytes allowing adoptive cell therapy enhanced by oncolytic adenovirus in a replication permissive setting

References

• Rosenberg SA, Spiess P, Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 1986; 233:1318-21; PMID:3489291; http://dx.doi.org/10.1126/science.3489291
   PubMed Web of Science ®Google Scholar
• Hinrichs CS, Rosenberg SA. Exploiting the curative potential of adoptive T-cell therapy for cancer. Immunol Rev 2014; 257:56-71; PMID:24329789; http://dx.doi.org/10.1111/imr.12132
   PubMed Web of Science ®Google Scholar
• Rosenberg SA. IL-2: The first effective immunotherapy for human cancer. J Immunol 2014; 192:5451-8; PMID:24907378; http://dx.doi.org/10.4049/jimmunol.1490019
   PubMed Web of Science ®Google Scholar
• Jiang H, Gomez-Manzano C, Lang FF, Alemany R, Fueyo J. Oncolytic adenovirus: Preclinical and clinical studies in patients with human malignant gliomas. Curr Gene Ther 2009; 9:422-7; PMID:19860656; http://dx.doi.org/10.2174/156652309789753356
   PubMed Web of Science ®Google Scholar
• Pol J, Bloy N, Obrist F, Eggermont A, Galon J, Cremer I, Erbs P, Limacher JM, Preville X, Zitvogel L et al. Trial watch: Oncolytic viruses for cancer therapy. Oncoimmunology 2014; 3:e28694; PMID:25097804; http://dx.doi.org/10.4161/onci.28694
   PubMed Web of Science ®Google Scholar
• Bressy C, Benihoud K. Association of oncolytic adenoviruses with chemotherapies: An overview and future directions. Biochem Pharmacol 2014; 90:97-106; PMID:24832861; http://dx.doi.org/10.1016/j.bcp.2014.05.003
   PubMed Web of Science ®Google Scholar
• Zamarin D, Pesonen S. Replication-competent viruses as cancer immunotherapeutics: Emerging clinical data. Hum Gene Ther 2015; 26:538-49; PMID:26176173; http://dx.doi.org/10.1089/hum.2015.055
   PubMed Web of Science ®Google Scholar
• Thomas MA, Spencer JF, La Regina MC, Dhar D, Tollefson AE, Toth K, Wold WS. Syrian hamster as a permissive immunocompetent animal model for the study of oncolytic adenovirus vectors. Cancer Res 2006; 66:1270-6; PMID:16452178; http://dx.doi.org/10.1158/0008-5472.CAN-05-3497
   PubMed Web of Science ®Google Scholar
• Cerullo V, Pesonen S, Diaconu I, Escutenaire S, Arstila PT, Ugolini M, Nokisalmi P, Raki M, Laasonen L, Sarkioja M et al. Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients. Cancer Res 2010; 70:4297-309]; PMID:20484030; http://dx.doi.org/10.1158/0008-5472.CAN-09-3567
   PubMed Web of Science ®Google Scholar
• Wold WS, Toth K. Chapter three–syrian hamster as an animal model to study oncolytic adenoviruses and to evaluate the efficacy of antiviral compounds. Adv Cancer Res 2012; 115:69-92; PMID:23021242; http://dx.doi.org/10.1016/B978-0-12-398342-8.00003-3
   PubMed Web of Science ®Google Scholar
• Besser MJ, Shapira-Frommer R, Treves AJ, Zippel D, Itzhaki O, Hershkovitz L, Levy D, Kubi A, Hovav E, Chermoshniuk N et al. Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients. Clin Cancer Res 2010; 16:2646-55; PMID:20406835; http://dx.doi.org/10.1158/1078-0432.CCR-10-0041
   PubMed Web of Science ®Google Scholar
• Tran KQ, Zhou J, Durflinger KH, Langhan MM, Shelton TE, Wunderlich JR, Robbins PF, Rosenberg SA, Dudley ME. Minimally cultured tumor-infiltrating lymphocytes display optimal characteristics for adoptive cell therapy. J Immunother 2008; 31:742-51; PMID:18779745; http://dx.doi.org/10.1097/CJI.0b013e31818403d5
   PubMed Web of Science ®Google Scholar
• Besser MJ, Shapira-Frommer R, Treves AJ, Zippel D, Itzhaki O, Schallmach E, Kubi A, Shalmon B, Hardan I, Catane R et al. Minimally cultured or selected autologous tumor-infiltrating lymphocytes after a lympho-depleting chemotherapy regimen in metastatic melanoma patients. J Immunother 2009; 32:415-23; PMID:19342963; http://dx.doi.org/10.1097/CJI.0b013e31819c8bda
   PubMed Web of Science ®Google Scholar
• Donia M, Junker N, Ellebaek E, Andersen MH, Straten PT, Svane IM. Characterization and comparison of “standard” and “young” tumor infiltrating lymphocytes for adoptive cell therapy at a danish translational research institution. Scand J Immunol 2011; 75:157-167; PMID:21955245; http://dx.doi.org/10.1111/j.1365-3083.2011.02640.x
   PubMed Web of Science ®Google Scholar
• Itzhaki O, Hovav E, Ziporen Y, Levy D, Kubi A, Zikich D, Hershkovitz L, Treves AJ, Shalmon B, Zippel D et al. Establishment and large-scale expansion of minimally cultured “young” tumor infiltrating lymphocytes for adoptive transfer therapy. J Immunother 2011; 34:212-20; PMID:21304398; http://dx.doi.org/10.1097/CJI.0b013e318209c94c
   PubMed Web of Science ®Google Scholar
• Dudley ME, Gross CA, Somerville RP, Hong Y, Schaub NP, Rosati SF, White DE, Nathan D, Restifo NP, Steinberg SM et al. Randomized selection design trial evaluating CD8+-enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanoma. J Clin Oncol 2013; 31:2152-9; PMID:23650429; http://dx.doi.org/10.1200/JCO.2012.46.6441
   PubMed Web of Science ®Google Scholar
• Bramante S, Kaufmann JK, Veckman V, Liikanen I, Nettelbeck DM, Hemminki O, Vassilev L, Cerullo V, Oksanen M, Heiskanen R et al. Treatment of melanoma with a serotype 5/3 chimeric oncolytic adenovirus coding for GM-CSF: Results in vitro, in rodents and in humans. Int J Cancer 2015; 137:1775-83; PMID:25821063; http://dx.doi.org/10.1002/ijc.29536
   PubMed Web of Science ®Google Scholar
• Diaconu I, Cerullo V, Hirvinen ML, Escutenaire S, Ugolini M, Pesonen SK, Bramante S, Parviainen S, Kanerva A, Loskog AS et al. Immune response is an important aspect of the antitumor effect produced by a CD40L-encoding oncolytic adenovirus. Cancer Res 2012; 72:2327-38; PMID:22396493; http://dx.doi.org/10.1158/0008-5472.CAN-11-2975
   PubMed Web of Science ®Google Scholar
• Kanerva A, Nokisalmi P, Diaconu I, Koski A, Cerullo V, Liikanen I, Tahtinen S, Oksanen M, Heiskanen R, Pesonen S et al. Antiviral and antitumor T-cell immunity in patients treated with GM-CSF-coding oncolytic adenovirus. Clin Cancer Res 2013; 19:2734-44; PMID:23493351; http://dx.doi.org/10.1158/1078-0432.CCR-12-2546
   PubMed Web of Science ®Google Scholar
• Hemminki O, Parviainen S, Juhila J, Turkki R, Linder N, Lundin J, Kankainen M, Ristimaki A, Koski A, Liikanen I et al. Immunological data from cancer patients treated with Ad5/3-E2F-Delta24-GMCSF suggests utility for tumor immunotherapy. Oncotarget 2015; 6:4467-81; PMID:25714011; http://dx.doi.org/10.18632/oncotarget.2901
   PubMed Web of Science ®Google Scholar
• Cerullo V, Diaconu I, Romano V, Hirvinen M, Ugolini M, Escutenaire S, Holm SL, Kipar A, Kanerva A, Hemminki A. An oncolytic adenovirus enhanced for toll-like receptor 9 stimulation increases antitumor immune responses and tumor clearance. Mol Ther 2012; 20:2076-86; PMID:22828500; http://dx.doi.org/10.1038/mt.2012.137
   PubMed Web of Science ®Google Scholar
• Zhu J, Yamane H, Paul WE. Differentiation of effector CD4 T cell populations (*). Annu Rev Immunol 2010; 28:445-89; PMID:20192806; http://dx.doi.org/10.1146/annurev-immunol-030409-101212
   PubMed Web of Science ®Google Scholar
• Geginat J, Paroni M, Maglie S, Alfen JS, Kastirr I, Gruarin P, De Simone M, Pagani M, Abrignani S. Plasticity of human CD4 T cell subsets. Front Immunol 2014; 5:630; PMID:25566245; http://dx.doi.org/10.3389/fimmu.2014.00630
   PubMed Web of Science ®Google Scholar
• Nishikawa H, Sakaguchi S. Regulatory T cells in cancer immunotherapy. Curr Opin Immunol 2014; 27:1-7; PMID:24413387; http://dx.doi.org/10.1016/j.coi.2013.12.005
   PubMed Web of Science ®Google Scholar
• Muranski P, Restifo NP. Adoptive immunotherapy of cancer using CD4(+) T cells. Curr Opin Immunol 2009; 21:200-8; PMID:19285848; http://dx.doi.org/10.1016/j.coi.2009.02.004
   PubMed Web of Science ®Google Scholar
• Quezada SA, Simpson TR, Peggs KS, Merghoub T, Vider J, Fan X, Blasberg R, Yagita H, Muranski P, Antony PA et al. Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J Exp Med 2010; 207:637-50 PMID:20156971; http://dx.doi.org/10.1084/jem.20091918
   PubMed Web of Science ®Google Scholar
• Matsuzaki J, Tsuji T, Luescher I, Old LJ, Shrikant P, Gnjatic S, Odunsi K. Nonclassical antigen-processing pathways are required for MHC class II-restricted direct tumor recognition by NY-ESO-1-specific CD4(+) T cells. Cancer Immunol Res 2014; 2:341-50; PMID:24764581; http://dx.doi.org/10.1158/2326-6066.CIR-13-0138
   PubMed Web of Science ®Google Scholar
• Siurala M, Bramante S, Vassilev L, Hirvinen M, Parviainen S, Tahtinen S, Guse K, Cerullo V, Kanerva A, Kipar A et al. Oncolytic adenovirus and doxorubicin-based chemotherapy results in synergistic antitumor activity against soft-tissue sarcoma. Int J Cancer 2015; 136:945-54; PMID:24975392; http://dx.doi.org/10.1002/ijc.29048
   PubMed Web of Science ®Google Scholar
• Rajecki M, af Hallstrom T, Hakkarainen T, Nokisalmi P, Hautaniemi S, Nieminen AI, Tenhunen M, Rantanen V, Desmond RA, Chen DT et al. Mre11 inhibition by oncolytic adenovirus associates with autophagy and underlies synergy with ionizing radiation. Int J Cancer 2009; 125:2441-9; PMID:19672857; http://dx.doi.org/10.1002/ijc.24608
   PubMed Web of Science ®Google Scholar
• Nishio N, Diaconu I, Liu H, Cerullo V, Caruana I, Hoyos V, Bouchier-Hayes L, Savoldo B, Dotti G. Armed oncolytic virus enhances immune functions of chimeric antigen receptor-modified T cells in solid tumors. Cancer Res 2014; 74:5195-205; PMID:25060519; http://dx.doi.org/10.1158/0008-5472.CAN-14-0697
   PubMed Web of Science ®Google Scholar
• Dudley ME, Wunderlich JR, Shelton TE, Even J, Rosenberg SA. Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J Immunother 2003; 26:332-42; PMID:12843795; http://dx.doi.org/10.1097/00002371-200307000-00005
   PubMed Web of Science ®Google Scholar
• Wu R, Forget MA, Chacon J, Bernatchez C, Haymaker C, Chen JQ, Hwu P, Radvanyi LG. Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: Current status and future outlook. Cancer J 2012; 18:160-75; PMID:22453018; http://dx.doi.org/10.1097/PPO.0b013e31824d4465
   PubMed Web of Science ®Google Scholar
• Kohlhapp FJ, Broucek JR, Hughes T, Huelsmann EJ, Lusciks J, Zayas JP, Dolubizno H, Fleetwood VA, Grin A, Hill GE et al. NK cells and CD8+ T cells cooperate to improve therapeutic responses in melanoma treated with interleukin-2 (IL-2) and CTLA-4 blockade. J Immunother Cancer 2015; 3:18, 015-0063-3. eCollection 2015; PMID:25992289; http://dx.doi.org/10.1186/s40425-015-0063-3
   PubMed Web of Science ®Google Scholar
• Church SE, Jensen SM, Antony PA, Restifo NP, Fox BA. Tumor-specific CD4+ T cells maintain effector and memory tumor-specific CD8+ T cells. Eur J Immunol 2014; 44:69-79; PMID:24114780; http://dx.doi.org/10.1002/eji.201343718
   PubMed Web of Science ®Google Scholar
• Li Y, Liu S, Hernandez J, Vence L, Hwu P, Radvanyi L. MART-1-specific melanoma tumor-infiltrating lymphocytes maintaining CD28 expression have improved survival and expansion capability following antigenic restimulation in vitro. J Immunol 2010; 184:452-65; PMID:19949105; http://dx.doi.org/10.4049/jimmunol.0901101
   PubMed Web of Science ®Google Scholar
• Tahtinen S, Gronberg-Vaha-Koskela S, Lumen D, Merisalo-Soikkeli M, Siurala M, Airaksinen AJ, Vaha-Koskela M, Hemminki A. Adenovirus improves the efficacy of adoptive T-cell therapy by recruiting immune cells to and promoting their activity at the tumor. Cancer Immunol Res 2015; 3:915-25; PMID:25977260; http://dx.doi.org/10.1158/2326-6066.CIR-14-0220-T
   PubMed Web of Science ®Google Scholar
• Vassilev L, Ranki T, Joensuu T, Jager E, Karbach J, Wahle C, Partanen K, Kairemo K, Alanko T, Turkki R et al. Repeated intratumoral administration of ONCOS-102 leads to systemic antitumor CD8 T-cell response and robust cellular and transcriptional immune activation at tumor site in a patient with ovarian cancer. Oncoimmunology 2015; 4:e1017702; PMID:26140248; http://dx.doi.org/10.1080/2162402X.2015.1017702
   PubMed Web of Science ®Google Scholar
• Kawai O, Ishii G, Kubota K, Murata Y, Naito Y, Mizuno T, Aokage K, Saijo N, Nishiwaki Y, Gemma A et al. Predominant infiltration of macrophages and CD8(+) T cells in cancer nests is a significant predictor of survival in stage IV nonsmall cell lung cancer. Cancer 2008; 113:1387-95; PMID:18671239 http://dx.doi.org/10.1002/cncr.23712
   PubMed Web of Science ®Google Scholar
• Pages F, Kirilovsky A, Mlecnik B, Asslaber M, Tosolini M, Bindea G, Lagorce C, Wind P, Marliot F, Bruneval P et al. In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. J Clin Oncol 2009; 27:5944-51; PMID:19858404; http://dx.doi.org/10.1200/JCO.2008.19.6147
   PubMed Web of Science ®Google Scholar
• Mina M, Boldrini R, Citti A, Romania P, D'Alicandro V, De Ioris M, Castellano A, Furlanello C, Locatelli F, Fruci D. Tumor-infiltrating T lymphocytes improve clinical outcome of therapy-resistant neuroblastoma. Oncoimmunology 2015; 4:e1019981; PMID:26405592; http://dx.doi.org/10.1080/2162402X.2015.1019981
   PubMed Web of Science ®Google Scholar
• Maykel J, Liu JH, Li H, Shultz LD, Greiner DL, Houghton J. NOD-scidIl2rg (tm1Wjl) and NOD-Rag1 (null) Il2rg (tm1Wjl) : A model for stromal cell-tumor cell interaction for human colon cancer. Dig Dis Sci 2014; 59:1169-79; PMID:24798995; http://dx.doi.org/10.1007/s10620-014-3168-5
   PubMed Web of Science ®Google Scholar
• Tahtinen S, Kaikkonen S, Merisalo-Soikkeli M, Gronberg-Vaha-Koskela S, Kanerva A, Parviainen S, Vaha-Koskela M, Hemminki A. Favorable alteration of tumor microenvironment by immunomodulatory cytokines for efficient T-cell therapy in solid tumors. PLoS One 2015; 10:e0131242; PMID:26107883; http://dx.doi.org/10.1371/journal.pone.0131242
   PubMed Web of Science ®Google Scholar
• Koski A, Kangasniemi L, Escutenaire S, Pesonen S, Cerullo V, Diaconu I, Nokisalmi P, Raki M, Rajecki M, Guse K et al. Treatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSF. Mol Ther 2010; 18:1874-84; PMID:20664527; http://dx.doi.org/10.1038/mt.2010.161
   PubMed Web of Science ®Google Scholar
• Gowen BB, Judge JW, Wong MH, Jung KH, Aylsworth CF, Melby PC, Rosenberg B, Morrey JD. Immunoprophylaxis of punta toro virus (phlebovirus, bunyaviridae) infection in hamsters with recombinant eimeria profilin-like antigen. Int Immunopharmacol 2008; 8:1089-94; PMID:18550012; http://dx.doi.org/10.1016/j.intimp.2008.03.019
   PubMed Web of Science ®Google Scholar
• Adusumilli PS, Cherkassky L, Villena-Vargas J, Colovos C, Servais E, Plotkin J, Jones DR, Sadelain M. Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity. Sci Transl Med 2014; 6:261ra151; PMID:25378643; http://dx.doi.org/10.1126/scitranslmed.3010162
   PubMed Web of Science ®Google Scholar
• Freedman RS, Edwards CL, Kavanagh JJ, Kudelka AP, Katz RL, Carrasco CH, Atkinson EN, Scott W, Tomasovic B, Templin S. Intraperitoneal adoptive immunotherapy of ovarian carcinoma with tumor-infiltrating lymphocytes and low-dose recombinant interleukin-2: A pilot trial. J Immunother Emphasis Tumor Immunol 1994; 16:198-210; PMID:7834119; http://dx.doi.org/10.1097/00002371-199410000-00004
   PubMed Web of Science ®Google Scholar
• Kanerva A, Zinn KR, Chaudhuri TR, Lam JT, Suzuki K, Uil TG, Hakkarainen T, Bauerschmitz GJ, Wang M, Liu B et al. Enhanced therapeutic efficacy for ovarian cancer with a serotype 3 receptor-targeted oncolytic adenovirus. Mol Ther 2003; 8:449-58; PMID:12946318; http://dx.doi.org/10.1016/S1525-0016(03)00200-4
   PubMed Web of Science ®Google Scholar
• Hammerbeck CD, Hooper JW. T cells are not required for pathogenesis in the syrian hamster model of hantavirus pulmonary syndrome. J Virol 2011; 85:9929-44; PMID:21775442; http://dx.doi.org/10.1128/JVI.05356-11
   PubMed Web of Science ®Google Scholar
• Ying B, Toth K, Spencer JF, Aurora R, Wold WS. Transcriptome sequencing and development of an expression microarray platform for liver infection in adenovirus type 5-infected syrian golden hamsters. Virology 2015; 485:305-12; PMID:26319212; http://dx.doi.org/10.1016/j.virol.2015.07.024
   PubMed Web of Science ®Google Scholar
• Lobigs M, Mullbacher A, Blanden RV, Hammerling GJ, Momburg F. Antigen presentation in syrian hamster cells: Substrate selectivity of TAP controlled by polymorphic residues in TAP1 and differential requirements for loading of H2 class I molecules. Immunogenetics 1999; 49:931-41; PMID:10501835; http://dx.doi.org/10.1007/s002510050576
   PubMed Web of Science ®Google Scholar
• Claesson MH, Endel B, Ulrik J, Pedersen LO, Skov S, Buus S. Antibodies directed against monomorphic and evolutionary conserved self epitopes may be generated in ‘knock-out’ mice. development of monoclonal antibodies directed against monomorphic MHC class I determinants. Scand J Immunol 1994; 40:257-64PMID:7519360; http://dx.doi.org/10.1111/j.1365-3083.1994.tb03459.x
   PubMed Web of Science ®Google Scholar